Clinical Trial Update: Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluated the combination of fludarabine and rituximab for marginal zone non-Hodgkin's lymphoma (MALT lymphoma) and has completed with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Marginal Zone Lymphoma
• Mucosa-associated Lymphoid Tissue Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Fludarabine (Fludarabine)
• Rituximab (rituximab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Lymphoma, Non-Hodgkin, MALT Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2014-10-06